A multinational pharmaceutical company headquartered in Japan is actively looking globally for opportunities to in-license cutting-edge, early stage therapeutic assets. The pharma also has a large USA-based subsidiary. Sponsored research may also be considered with a focus on Japan-based academic institutions.
The firm’s external R&D is focused on both neurodegenerative and neurodevelopmental diseases including Parkinson’s disease, autism, Rett Syndrome, fragile X, and lysosomal storage diseases. The firm is interested in platform technology and early stage hits/seeds in CNS/neurology. This includes new MOAs such as gene therapy, stem cell therapy, BBB penetrating biologics and monoclonal antibodies acting on new targets. The firm is also interested in later-stage assets (phase III to on the market) in diabetes, immunology, and infectious diseases for the Asia markets.
The firm is looking for assets that would be strategic a fit with its current portfolio. The firm is willing to negotiate regional rights based each therapeutic field. For example, in immunology and neurology, the firm would prefer both US and Asia rights. In diabetes, infectious diseases, and other areas, the firm can request Asia rights only.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply